Q-omics provides the consensus-scored CLMAT3 profile across patient tissues and cancer cell-line models. CLMAT3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CLMAT3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CLMAT3 RNA expression shows 17,944 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where CLMAT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLMAT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLMAT3 survival associations across molecular data types. CLMAT3 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLMAT3 RNA expression–survival associations across cancer types. High CLMAT3 expression shows unfavorable associations in UVM, BLCA, STAD and KIRC, but favorable associations in HNSC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for CLMAT3 RNA expression.
This table summarizes CLMAT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CLMAT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLMAT3 shows lower tumor expression in BRCA, THCA and LUAD and higher tumor expression in KIRC, COAD and HNSC. The KIRC box plot shows higher CLMAT3 RNA expression in tumor versus normal tissue (log2 FC = +0.179, t-test p < 0.001).
This table shows molecular features associated with CLMAT3 in patient tissues and cancer cell lines. In patient samples, CLMAT3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
